Voglio sapere a riguardo di…

Federal Register / Vol. 86, No. 130 / Monday, July 12, 2021 / Notices Maryland 20852. Phone: 2404536173;
email: COVID19HETF@hhs.gov.
SUPPLEMENTARY INFORMATION:
Background: The COVID19 Health Equity Task Force Task Force was established by Executive Order 13995, dated January 21, 2021. The Task Force is tasked with providing specific recommendations to the President, through the Coordinator of the COVID
19 Response and Counselor to the President COVID19 Response Coordinator, for mitigating the health inequities caused or exacerbated by the COVID19 pandemic and for preventing such inequities in the future. The Task Force shall submit a final report to the COVID19 Response Coordinator addressing any ongoing health inequities faced by COVID19 survivors that may merit a public health response, describing the factors that contributed to disparities in COVID19 outcomes, and recommending actions to combat such disparities in future pandemic responses.
The meeting is open to the public and will be live-streamed at www.hhs.gov/
live. No registration is required. A
public comment session will be held during the meeting. Pre-registration is required to provide public comment during the meeting. To pre-register, please send an email to COVID19HETF@hhs.gov and include your name, title, and organization by close of business on Friday, July 23, 2021. Comments will be limited to no more than three minutes per speaker
Dated: July 6, 2021.
Samuel Wu, Designated Federal Officer, COVID19 Health Equity Task Force.
FR Doc. 202114703 Filed 7921; 8:45 am BILLING CODE 415029P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health Prospective Grant of an Exclusive Patent License: Oligonucleotides Analogues Targeting Human LMNA
lamin A Gene AGENCY:

National Institutes of Health,
HHS.

ACTION:

Notice.

The National Human Genome Research Institute NHGRI, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive, Sublicensable Patent License to consolidate co-owned rights to the inventions and the Patents and Patent Applications listed in the Supplementary Information section of this notice to The Progeria Research Foundation PRF, having a place of business in 200 Lake Street, Unit 102, Peabody, MA 01960.

SUMMARY:

Only written comments and/or applications for a license that are received by the NHGRI Office of Technology Transfer Office on or before July 27, 2021 will be considered.

DATES:

Requests for a copy of the patent applications, inquiries, and comments relating to the contemplated license should be directed to: Eggerton Campbell, License and Patent Manager, NHGRI Technology Transfer Office, Telephone: 3014021648; email:
eggerton.campbell@nih.gov.

ADDRESSES:

The following and all continuing U.S. and foreign patents/patent applications thereof are the intellectual properties to be licensed under the prospective agreement:

SUPPLEMENTARY INFORMATION:

Country
Title
United States

Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E04420130US01.
Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E04420130PCT03.
Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E04420130GB12.
Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E04420130US02.
Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E04420130US06.
Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E04420130US07.
Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E04420130EP04.
Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E04420130JP15.
Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E04420130FR11.
Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E04420130DE10.
Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E04420130IE13.
Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E04420130JP05.
Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E04420130JP08.
Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E04420130NL14.
Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E04420130CH09.
Oligonucleotide Analogues Targeting Human LMNA NIH E04420131US01
Oligonucleotide Analogues Targeting Human LMNA NIH E04420131PCT02

WIPO
United Kingdom
United States
United States
United States
Europe
Japan
France
Germany
Ireland
Japan
khammond on DSKJM1Z7X2PROD with NOTICES

and should be pertinent to the meeting discussion. Individuals are encouraged to provide a written statement of any public comments for accurate minutetaking purposes. If you decide you would like to provide public comment but do not pre-register, you may submit your written statement by emailing COVID19HETF@hhs.gov no later than close of business on Thursday, August 5, 2021. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact: COVID19HETF@hhs.gov and reference this meeting. Requests for special accommodations should be made at least 10 business days prior to the meeting.

Japan
Netherlands
Switzerland
United States
WIPO

VerDate Sep<11>2014

17:26 Jul 09, 2021

Jkt 253001

PO 00000

Frm 00042

Fmt 4703

Application No.

Sfmt 4703

36563

E:FRFM12JYN1.SGM

12JYN1

Patent No.

61/568,590.
PCT/US12/068609
WO 2013/086444.
12806796.4

2788488

13/708,709

9,326,992

15/084,255

9,833,468

15/727,483 CON ..

10,398,721

12806796.4

2788488

2019109410.
12806796.4

2788488

12806796.4

2788488

12806796.4

2788488

2014546152

6132849

201741744.
12806796.4

2788488

12806796.4

2788488

62/330,027.
PCT/US17/30174
WO 2017/190041.